Dasatinib Active Not Recruiting Phase 2 Trials for Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Blastic Phase / Recurrent Disease / Childhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Relapsing Chronic Myelogenous Leukemia / Chronic Phase of Disease / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Recurrent Adult Acute Lymphoblastic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Adult Acute Lymphoblastic Leukemia in Remission Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00070499Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00036738Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib